The Europe In Situ Hybridization Market would witness market growth of 6.5% CAGR during the forecast period (2022-2028).
The localization of gene expression in a cellular context is shown by in situ hybridization. A sample's known target mRNA or DNA sequence may be found using a labeled RNA or DNA probe to hybridize it. Then, an antibody may be used to recognize the label on the labeled RNA or DNA probe. Therefore, the probes may be utilized to find the mRNA's location and the expression of an interest gene.
Numerous congenital and acquired neurological disorders, including intellectual impairments, congenital malformations, and primary central nervous system tumors, have a molecular genesis involving structural and numerical changes to the healthy human diploid genome. Chromosome microarray analysis (CMA), also known as fluorescence in situ hybridization (FISH) and, more lately, microarray-based genomic hybridization techniques, are now regarded as essential tools for both clinical diagnosis and treatment of patients with these diseases as well as for scientific research.
The medical technology market in Germany is the largest in all of Europe. The German medical device industry, which accounts for around USD 35.8 billion yearly or 25.6% of the whole European market, is one of the most profitable healthcare markets in the world. The region's strong and well-developed medical technology sector is expected to demonstrate the adoption of ISH-type technologies. Thus, it is projected that the market for in situ hybridization will grow in the region due to the rising prevalence of cancer and the growing acceptability of cutting-edge medical technology.
The Germany market dominated the Europe In Situ Hybridization Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $114.7 million by 2028.The UK market is anticipated to grow at a CAGR of 5.6% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.2% during (2022 - 2028).
Based on Technology, the market is segmented into Fluorescent In Situ Hybridization (FISH) and Chromogenic In Situ Hybridization (CISH). Based on End Use, the market is segmented into Research & Diagnostic Laboratories, Academic Institutes, CROs and Others. Based on Application, the market is segmented into Cancer, Cytogenetics, Developmental Biology, Infectious Diseases and Others. Based on Product, the market is segmented into Instruments, Kits & Probes, Software and Services. Based on Probe, the market is segmented into DNA and RNA. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global In Situ Hybridization Market will Hit $1.8 Billion by 2028, at a CAGR of 6.9%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
By Technology
By End Use
By Application
By Product
By Probe
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
